Windlas Biotech Quarterly Results
Windlas Biotech quarterly results. In Sept 2025, Windlas Biotech (WINDLAS) reported revenue ₹226 Cr and net profit ₹18 Cr — revenue +17.7% YoY. For annual financials, live price and key ratios, visit WINDLAS share price.
WINDLAS Quarterly Results — Revenue, Profit & EPS Highlights
Windlas Biotech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check WINDLAS market cap trends to track the company's total market size over time.
- Revenue of ₹226 Cr in Sept 2025 (+8.7% vs Mar 2025, +17.7% vs Sept 2024)
- Net Profit of ₹18 Cr in Sept 2025 (+12.5% vs Mar 2025, +12.5% vs Sept 2024)
- EBITDA of ₹32 Cr in Sept 2025 (+3.2% vs Mar 2025)
- Operating Margin of 13.0% in Sept 2025 (+0.0pp vs Mar 2025)
- Earnings Per Share of ₹8.48 in Sept 2025 (+9.1% vs Mar 2025)
Windlas Biotech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
WINDLAS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 226 | 208 | 215 | 238 | 192 | 8.7% | 17.7% |
| Net Profit (₹ Cr) | 18 | 16 | 18 | 15 | 16 | - | - |
| EBITDA (₹ Cr) | 32 | 31 | 32 | 29 | 28 | - | - |
| EPS (₹) | 8.48 | 7.77 | 8.43 | 7.12 | 7.49 | - | - |
| Operating Margin (%) | 13.0% | 13.0% | 13.0% | 10.0% | 12.0% | - | - |
WINDLAS Share Price Trend — 1-Year Movement Across Quarterly Results
Windlas Biotech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review Windlas Biotech P/E valuation to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
WINDLAS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Windlas Biotech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores